CN1921849A - 包含具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的肥胖症的联合治疗 - Google Patents

包含具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的肥胖症的联合治疗 Download PDF

Info

Publication number
CN1921849A
CN1921849A CNA2004800300871A CN200480030087A CN1921849A CN 1921849 A CN1921849 A CN 1921849A CN A2004800300871 A CNA2004800300871 A CN A2004800300871A CN 200480030087 A CN200480030087 A CN 200480030087A CN 1921849 A CN1921849 A CN 1921849A
Authority
CN
China
Prior art keywords
compound
lipase
obesity
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800300871A
Other languages
English (en)
Chinese (zh)
Inventor
J·安特尔
H·G·克劳瑟
P-C·格雷戈里
M·乌尔
H·沃尔德克
J·H·M·兰格
C·G·克鲁泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of CN1921849A publication Critical patent/CN1921849A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800300871A 2003-10-24 2004-10-22 包含具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的肥胖症的联合治疗 Pending CN1921849A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03103961.3 2003-10-24
EP03103961 2003-10-24

Publications (1)

Publication Number Publication Date
CN1921849A true CN1921849A (zh) 2007-02-28

Family

ID=34486362

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800300871A Pending CN1921849A (zh) 2003-10-24 2004-10-22 包含具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的肥胖症的联合治疗
CNA2004800301164A Pending CN1997364A (zh) 2003-10-24 2004-10-22 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004800301164A Pending CN1997364A (zh) 2003-10-24 2004-10-22 显示cb1－拮抗活性的化合物的新医学用途和包含所述化合物的联合治疗

Country Status (13)

Country Link
EP (1) EP1680106B1 (https=)
JP (1) JP2007509110A (https=)
CN (2) CN1921849A (https=)
AR (1) AR046132A1 (https=)
AT (1) ATE438394T1 (https=)
AU (1) AU2004283055A1 (https=)
BR (1) BRPI0415463A (https=)
CA (1) CA2543342A1 (https=)
DE (1) DE602004022445D1 (https=)
MX (1) MXPA06004390A (https=)
RU (1) RU2006117639A (https=)
TW (1) TW200528102A (https=)
WO (1) WO2005039566A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795229C2 (ru) * 2018-11-20 2023-05-02 Шанхайтек Юниверсити Ингибиторы mmpl3, композиции на их основе и пути их применения

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039996A (ko) * 2005-08-17 2008-05-07 솔베이 파머슈티컬스 게엠베하 칼륨 채널 억제 화합물의 사용 방법
CN102731418B (zh) * 2012-07-15 2015-03-11 浙江大学 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
CN113166068B (zh) * 2018-11-20 2024-08-16 上海科技大学 MmpL3抑制剂、组合物及其用途
CN117551046B (zh) * 2023-11-17 2025-10-28 广东药科大学附属第一医院 二氨基脲类hsl抑制剂、制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3335A1 (fr) * 2000-03-23 2001-09-27 Solvay Pharm Bv Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1
PL363751A1 (en) * 2001-03-22 2004-11-29 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
KR100903760B1 (ko) * 2001-09-21 2009-06-19 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체
IL157704A0 (en) * 2001-09-21 2004-03-28 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity
SE0104330D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
RU2344132C2 (ru) * 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
MXPA06002064A (es) * 2003-10-20 2006-05-19 Solvay Pharm Bv Derivados e 1h imidazol como moduladores del receptor cannabinoide.
MXPA06004434A (es) * 2003-10-24 2006-06-20 Solvay Pharm Gmbh Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795229C2 (ru) * 2018-11-20 2023-05-02 Шанхайтек Юниверсити Ингибиторы mmpl3, композиции на их основе и пути их применения
RU2795229C9 (ru) * 2018-11-20 2023-05-30 Шанхайтек Юниверсити Ингибиторы mmpl3, композиции на их основе и пути их применения

Also Published As

Publication number Publication date
JP2007509110A (ja) 2007-04-12
CA2543342A1 (en) 2005-05-06
EP1680106B1 (en) 2009-08-05
DE602004022445D1 (de) 2009-09-17
BRPI0415463A (pt) 2006-12-19
RU2006117639A (ru) 2007-12-10
TW200528102A (en) 2005-09-01
EP1680106A1 (en) 2006-07-19
AU2004283055A1 (en) 2005-05-06
CN1997364A (zh) 2007-07-11
WO2005039566A1 (en) 2005-05-06
ATE438394T1 (de) 2009-08-15
AR046132A1 (es) 2005-11-23
MXPA06004390A (es) 2006-06-14

Similar Documents

Publication Publication Date Title
CN1615134A (zh) 含有缬沙坦和nep抑制剂的药物组合物
CN1406128A (zh) 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用
US20050124660A1 (en) Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
TW200845983A (en) Methods of treating or preventing emesis using growth hormone secretagogues
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
CA2543338A1 (en) Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
CN1859913A (zh) 改善肾功能损伤个体多尿症的方法
CN1921849A (zh) 包含具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的肥胖症的联合治疗
CN100339073C (zh) 作为血清素拮抗剂用于治疗肥胖的芳基磺酰胺
CN86107991A (zh) 抗高血压复合物
CN101060832A (zh) 非水液体肠胃外醋氯芬酸配方
US20050143441A1 (en) Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
JP2005509631A (ja) Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
HK1101029A (en) Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors
CN1764453A (zh) 腹泻为主大肠激惹综合征的治疗制剂
CN1867332A (zh) 包含选择性cb1－拮抗剂和脂肪酶抑制剂的肥胖症的联合治疗
JP5559696B2 (ja) 糖尿病性腎症の治療剤
HK1096292A (en) Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
CN1835747A (zh) 具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物的用途
WO2009035368A1 (en) Antidiabetic pharmaceutical composition
US10034871B2 (en) Salts and compositions useful for treating disease
CN118251223A (zh) 包含血管紧张素受体阻断剂和sglt2抑制剂的复合组合物
WO2008127893A1 (en) Niacin-based pharmaceutical compositions
JPWO2007139062A1 (ja) 肥満治療剤並びに肥満の治療及び予防方法
JP2008179574A (ja) ピペラジン誘導体を有効成分とする糖化最終産物形成阻害剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101029

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070228

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1101029

Country of ref document: HK